Global Pancreatic Cancer Treatment Market, By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Others), Diagnosis (Blood Test, Biopsy, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the pancreatic cancer treatment market is anticipated to grow rapidly during the forecast period. Pancreatic cancer accounts for about 3% of all cancer in the United States, as per the American Cancer Society (ACS). The American Cancer Society estimates that 60,430 persons were diagnosed with pancreatic cancer in 2021. Because pancreatic cancer is difficult to detect, it is frequently discovered only after it has progressed to an advanced stage. Jaundice and weight loss are two symptoms of pancreatic cancer. Diabetes and exposure to some toxins are both risk factors. The type of treatment depends on the tumor's size and location and whether it has spread to other parts of the body.
Data Bridge Market Research analyses that the pancreatic cancer treatment market was valued at USD 2,236.17 million in 2021 and is expected to reach USD 6,245.81 million by 2029, registering a CAGR of 13.70% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
When uncontrolled cell development in a region of the pancreas occurs, pancreatic cancer develops. Jaundice and abdominal pain are common symptoms, but they may not show up until later in the disease's progression. The pancreas is in the back of the belly, near the gallbladder, behind the stomach. It is made up of glands that produce hormones and enzymes, including insulin. Pancreatic cancer is rarely discovered in its earliest stages, when it is most treatable. This is because it frequently does not manifest symptoms until it has progressed to other organs. The disease's severity determines treatment choices for pancreatic cancer. Surgery, chemotherapy, radiation therapy, or a combination of these treatments are all possible options.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2019 - 2014)
Revenue in USD Million, Volumes in Units, Pricing in USD
Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Others), Diagnosis (Blood Test, Biopsy, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Zydus Cadila (India), AstraZeneca (UK), Johnson & Johnson (US), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Amgen Inc. (US), Achieve Life Sciences, Inc (US), Infinity Pharmaceuticals Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Astellas Pharma Inc. (Japan)
Pancreatic Cancer Treatment Market Dynamics
- Increasing prevalence of cancer
The rising prevalence of cancer is estimated to enhance the market's growth. BRCA2 gene mutation, Lynch syndrome, and familial atypical mole-malignant melanoma (FAMMM) syndrome are types of genetic abnormalities that might raise cancer risk in the family. The rising incidences of diabetes and obesity will increase the risk of pancreatic cancer, hence influencing the market dynamics.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of pancreatic cancer treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get pancreatic cancer treatment, further estimated to enhance the market's growth rate.
Furthermore, rising initiatives by public and private organizations to spread awareness and advancements in molecular biology will expand the pancreatic cancer treatment market. Additionally, increasing addiction to smoking and growing tobacco consumption will result in expanding the pancreatic cancer treatment market.
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the pancreatic cancer treatment market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the pancreatic cancer treatment market growth during the forecast period.
On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the pancreatic cancer treatment market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This pancreatic cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pancreatic cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
According to the American Cancer Society, pancreatic cancer accounts for about 3% of all malignancies and 7% of all cancer deaths in the United States. Men are slightly more likely than women to get the condition.
Pancreatic cancer treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Pancreatic Cancer Treatment Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in pneumonia cases. This virus spread quickly over the world, killing many people. COVID-19 was labeled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the pancreatic cancer treatment market.
- In January 2022, U.S. Food and Drug Administration (FDA) had granted orphan drug designation to multitargeted T-cell therapy for the treatment of pancreatic cancer. MT-601 (Marker Therapeutics) is an autologous, nongene-edited T-cell treatment made up of cytotoxic T lymphocyte lines that attack cancer cells' surface proteins PRAME, SSX2, MAGEA4, NY-ESO-1, and Survivin.
Global Pancreatic Cancer Treatment Market Scope
The pancreatic cancer treatment market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Targeted Therapy
- Hormone Therapy
- Blood Test
- Imaging Tests
- Computerized tomography (CT) scans
- Magnetic resonance imaging (MRI)
- Positron emission tomography (PET) scans
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Pancreatic Cancer Treatment Market Regional Analysis/Insights
The pancreatic cancer treatment market is analysed and market size insights and trends are provided by country, treatment type, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the pancreatic cancer treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the pancreatic cancer treatment market because of the rising cases of pancreatic cancer in this region. Additionally, rising healthcare expenditure and favorable government policies will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to the increasing level of disposable income in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Pancreatic Cancer Treatment Market Share Analysis
The Pancreatic cancer treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pancreatic cancer treatment market.
Some of the major players operating in the pancreatic cancer treatment market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Zydus Cadila (India)
- AstraZeneca (UK)
- Johnson & Johnson (US)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Bristol-Myers Squibb Company (US)
- Eli Lilly and Company (US)
- Amgen Inc. (US)
- Achieve Life Sciences, Inc (US)
- Infinity Pharmaceuticals Inc. (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Astellas Pharma Inc. (Japan)